<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="de">
	<id>https://wiki.hl7.de/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Pduhmharbeck</id>
	<title>Hl7wiki - Benutzerbeiträge [de]</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.hl7.de/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Pduhmharbeck"/>
	<link rel="alternate" type="text/html" href="https://wiki.hl7.de/index.php?title=Spezial:Beitr%C3%A4ge/Pduhmharbeck"/>
	<updated>2026-04-24T19:25:51Z</updated>
	<subtitle>Benutzerbeiträge</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>https://wiki.hl7.de/index.php?title=IG:HL7_diagnosis&amp;diff=2592</id>
		<title>IG:HL7 diagnosis</title>
		<link rel="alternate" type="text/html" href="https://wiki.hl7.de/index.php?title=IG:HL7_diagnosis&amp;diff=2592"/>
		<updated>2011-08-02T09:32:23Z</updated>

		<summary type="html">&lt;p&gt;Pduhmharbeck: /* Tumor Localization */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Representation of Diagnosis based on the Clinical Document Architecture Rel.2 for Healthcare in Germany&lt;br /&gt;
&lt;br /&gt;
Version 1.1&lt;br /&gt;
&lt;br /&gt;
==Introduction==&lt;br /&gt;
===Introduction===&lt;br /&gt;
===Scope===&lt;br /&gt;
&lt;br /&gt;
==Diagnosis Types==&lt;br /&gt;
&lt;br /&gt;
==Common Diagnosis Descriptions==&lt;br /&gt;
&lt;br /&gt;
==Diagnosis Model in HL7 V3==&lt;br /&gt;
&lt;br /&gt;
==Representation of Diagnosis in specific Codesystems==&lt;br /&gt;
&lt;br /&gt;
==Representation of Cancer Diagnosis==&lt;br /&gt;
===Introduction===&lt;br /&gt;
In this chapter, diagnostic aspects in documentation of tumor diseases will be discribed.&lt;br /&gt;
Different aspects of diagnostical discriptions of tumor diseases are discribed by ICD-O (Oncology)&lt;br /&gt;
and by further classifications to constitute the determination of expansion respectivly of the diseases stage.&lt;br /&gt;
&lt;br /&gt;
Last one is mostly classified by the TNM-System. &lt;br /&gt;
&lt;br /&gt;
Especially for hemato oncological diseases (Leukemias and Lymphomas), other systems (e.g. Ann-Arbor-Classification) are used.&lt;br /&gt;
TNM-System discribes:&lt;br /&gt;
&lt;br /&gt;
* Expansion of primary tumor (extent repectivly spread in distant organs)&lt;br /&gt;
* Affection of lymph nodes in lymph flow area&lt;br /&gt;
* Exisistence of distant metastasis.&lt;br /&gt;
&lt;br /&gt;
For not by TNM – System classifiable diseases or in addition to TNM-System there are a number of further classification systems:&lt;br /&gt;
* Ann Arbor&lt;br /&gt;
* Rai&lt;br /&gt;
* Binet&lt;br /&gt;
* CML-Phasen&lt;br /&gt;
* FAB&lt;br /&gt;
* Durie and Salmon&lt;br /&gt;
* Gleason-Score&lt;br /&gt;
&lt;br /&gt;
Discriptions can be found here:&lt;br /&gt;
http://www.med.uni-giessen.de/akkk/gtds/grafisch/doku/bd5f.htm&lt;br /&gt;
http://www.tumorzentren.de/tl_files/dokumente/adt_basis.pdf&lt;br /&gt;
&lt;br /&gt;
This list probably will be always incomplete because of the medical progress.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===ICD-O===&lt;br /&gt;
Third Edition of ICD-O [DIMDI, WHO] is the topical one. ICD-O consists of two axes, Topography- and Morphology-Axis.&lt;br /&gt;
In ICD-O, tumor can be classified by&lt;br /&gt;
* Site&lt;br /&gt;
* Tissue Structure (Histology)&lt;br /&gt;
* Biological behaviour (Dignity)&lt;br /&gt;
* Tissue  grading (mostly in two or four stages) &lt;br /&gt;
In this case, tissue structure and tissue grading is redundant.&lt;br /&gt;
Precisely:&lt;br /&gt;
The first four digits of morphology-code describe tissue-type.&lt;br /&gt;
The fifth one describes biological behaviour (dignity-code):&lt;br /&gt;
* /0 = benign&lt;br /&gt;
* /1 = neoplasm with uncertain or unknown behaviour&lt;br /&gt;
* /2 = Cancer in situ&lt;br /&gt;
* /3 = malignant, primary tumor&lt;br /&gt;
* /6 = malignant, metastasis (not used in tumor documentation)&lt;br /&gt;
* /9 = malignant, uncertain wether primary tumor or a metastatic&lt;br /&gt;
The sixth digit describes grading, differentiation or phenotype (Histology/Pathology):&lt;br /&gt;
* 1 = Grade I, well differentiated (Low grade) &lt;br /&gt;
* 2 = Grade II, moderately differentiated (Intermediate grade)&lt;br /&gt;
* 3 = Grade III, poorly differentiated (High grade)&lt;br /&gt;
* 4 = Grade IV, undifferentiated (High grade)&lt;br /&gt;
* 9 = Grade IX, grade cannot be assessed&lt;br /&gt;
For Leukemias and Lymphomas, the sixth digit signifies the immunophenotype&lt;br /&gt;
* 5 = T-Cell&lt;br /&gt;
* 6 = B-Cell, Pre-B-Cell, B-Ancestor-Cell&lt;br /&gt;
* 7 = Null-Cell, Not-T-Cell-Not-B-Cell&lt;br /&gt;
* 8 = NK-Cell, Natural Killer Cell&lt;br /&gt;
* 9 = Determination of Cell Type was not accomplished, not specified or not applicable&lt;br /&gt;
&lt;br /&gt;
TNM System describes&lt;br /&gt;
* Expansion of primary tumor (extent repectivly spread in distant organs)&lt;br /&gt;
* Affection of lymph nodes in lymph flow area&lt;br /&gt;
* Exisistence of distant metastasis&lt;br /&gt;
&lt;br /&gt;
For the topography axis, there exists an (hierarchical) enlargement, the ‘localisation key’ (Wagner, G. (HRSG.): Tumorlokalisationsschlüssel, 5. Auflage, Springer Verlag, Berlin, Heidelberg, New York, Tokyo 1993), which can supply at some positions clinical relevant differentiation.&lt;br /&gt;
The morphology axis is composed of a four-digit code for tissue basic structure, a characteristic number for dignity and an additional grading item.&lt;br /&gt;
The key itself does not contain all possible combinations of histology and dignity, but points out those ones, for whome exist special discriptions.&lt;br /&gt;
Vice versa not all combinations of basic structure and dignity are possible (so there is no ‘benign leukemia’). Not either there is a grading system available for all kinds of tumor. For some ones, additional information (for Example ‘Cell-line’) is used at the corresponding position.&lt;br /&gt;
&lt;br /&gt;
====Tumor Localization====&lt;br /&gt;
For Tumor-Coding first of all, the site is important. It will be classified by the Topography -Axis of ICD-O. Topographical -Codes of ICD-10 are based on chapter II (Neoplasm –C 00 – C 97) of ICD-10.&lt;br /&gt;
However, some of the topographical Codes of ICD-10 (Codes) are not used, because their content is discribed by histology- and digit-Codes of ICD-O. (e.g. Differentiation in situ/ infiltrated, melanoma vs. scin cancer).&lt;br /&gt;
&lt;br /&gt;
====Tumor Histology and Dignity	====&lt;br /&gt;
Furthermore, in ICD-O, tumor morphology i.e. tissue structure (histology) and biological behavior (dignity) is discribed by special Codes.&lt;br /&gt;
Tumor histology is coded by a four-digit number, which is assumed of the morphology-axis of Standardized Nomenclature of Patholoy (SNOP). Dignity-Code is attendant on morphology-Code, seperated by /.&lt;br /&gt;
Examples:&lt;br /&gt;
* 8060/0	squamous epithelium - papillomatose&lt;br /&gt;
* 8070/2	squamous epithelium – cancer in situ undifferentiated&lt;br /&gt;
* 8070/3	squamous epithelium – cancer undifferentiated&lt;br /&gt;
* 8070/6	squamous epithelium – cancer metastasis undifferentiated&lt;br /&gt;
&lt;br /&gt;
====Tumor Grading====&lt;br /&gt;
Grading is derived from the comparison of primary tissue with the neoplasm of this tissue.&lt;br /&gt;
There are five grading-degrees (s.o.) and further three degrees for Malignant Lymphoma.&lt;br /&gt;
Registration of tumor grading is also provided in TNM.&lt;br /&gt;
&lt;br /&gt;
====Qualifier of Tumor Formular====&lt;br /&gt;
ICD-O –Codes can be specified by the following qualifier:&lt;br /&gt;
 &lt;br /&gt;
Here ICD-O provides additionally the following codes for Lymphoma, which specify the Cell line:&lt;br /&gt;
B-Cell, T-Cell, Null-Cell Lymphoma.&lt;br /&gt;
ICD-O uses the Codes 1 – 9.&lt;br /&gt;
A detailled System is discribed in Chapter 9 under 9.5.2 and 9.53.&lt;br /&gt;
&lt;br /&gt;
====Example====&lt;br /&gt;
 &lt;br /&gt;
GRAPHIC IS MISSING&lt;br /&gt;
&lt;br /&gt;
DisplayName is only available in correlation to qualifiers. According to ICD-O-3 formation rule there are much more discriptions possible as ICD-Catalog proposes.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
===TNM Classification===&lt;br /&gt;
===Ann Arbor Classification===&lt;br /&gt;
===FIGO Stages===&lt;br /&gt;
===Gleason Score===&lt;br /&gt;
===Papanikolaou===&lt;br /&gt;
===WHO Grading===&lt;br /&gt;
===Conclusion===&lt;br /&gt;
&lt;br /&gt;
 &lt;br /&gt;
==Cancer Diagnosis in HL7 V3==&lt;br /&gt;
&lt;br /&gt;
==Representation for specific Use Cases==&lt;br /&gt;
&lt;br /&gt;
==Terminology==&lt;br /&gt;
===Introduction===&lt;br /&gt;
===...===&lt;br /&gt;
&lt;br /&gt;
==Appendix A: Other==&lt;br /&gt;
&lt;br /&gt;
==Appendix B: Indices==&lt;/div&gt;</summary>
		<author><name>Pduhmharbeck</name></author>
		
	</entry>
</feed>